Wilmot Cancer Institute at Webster — Webster, New York

Wilmot Cancer Institute at Webster is a clinical research site located in Webster, New York, United States 14580.

Crixeo Clinical Trials Trust Score: 27/100 (FAILING). This profile has not yet been claimed by the site owner.

Wilmot Cancer Institute at Webster has participated in 55 clinical trials with 51 currently active.

Therapeutic areas: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8, Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma.

Sponsors: National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group, NRG Oncology.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Webster

Browse all research sites in New York · View every site in Webster

Sponsor Feasibility Report

Trust Score: 27/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Wilmot Cancer Institute at Webster?

Wilmot Cancer Institute at Webster has a Crixeo Trust Score of 27/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Wilmot Cancer Institute at Webster conducted?

Wilmot Cancer Institute at Webster has 55 clinical trials on record, with 51 currently active. Their work covers Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8, Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma.

Is Wilmot Cancer Institute at Webster accredited by Crixeo Clinical Trials?

Wilmot Cancer Institute at Webster has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Wilmot Cancer Institute at Webster?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.